Compare TransMedics Group Inc (TMDX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Veritone Inc — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while Veritone Inc trades at $0.56 (market cap $59.46M). The key difference: TransMedics Group Inc is far larger — about 46.1× Veritone Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Veritone Inc for 12 Days on average.
| TMDX | VERI | |
|---|---|---|
Market Cap | $2.74B | $59.46M |
Volume | 949,331 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $150.42 | $8.39 |
52-Week Low | $61.99 | $0.56 |
Typical Hold Time | 24 Days | 12 Days |
Enterprise Value | $3.13B | $94.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
VERI stock trades at $0.5851, down 15.36% in 24 hours, reflecting significant bearish technical momentum. The company reported a net loss of $111.73 million on $92.19 million revenue in 2025, with negative profitability margins. Recent news includes a $15 million equity offering and partnerships with ATP Media and ZeroEyes, but legal investigations and consistent earnings misses add uncertainty. Analyst consensus is mixed with a $3.75 price target, suggesting substantial potential upside from current levels if operational improvements materialize.
The outlook remains high-risk due to persistent losses and cash burn, offset by analyst optimism for long-term AI growth. Investment opportunity hinges on successful cost reduction and revenue acceleration from new partnerships. Key risks include ongoing legal scrutiny, competitive pressures, and the need for additional financing to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
